Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

Published:2023-12-27 Issue: Volume: Page:
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Li Xiaojiao^ORCID,Li Bing,Wang Meng,Fang Min,Lou Jinfeng,Liu Jingrui,Chen Hong,Ding Yanhua

Funder

the National Natural Science Foundation of China

Natural Science Foundation of Jilin Province

Norman Bethune Program of Jilin University

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-023-00637-y.pdf

Reference19 articles.

1. Akhil A, Bansal R, Anupam K, Tandon A, Bhatnagar A. Systemic lupus erythematosus: latest insight into etiopathogenesis. Rheumatol Int. 2023;43(8):1381–93. https://doi.org/10.1007/s00296-023-05346-x.

2. Zucchi D, Silvagni E, Elefante E, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol. 2023;41(5):997–1008. https://doi.org/10.55563/clinexprheumatol/4uc7e8.

3. Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician’s perspective. Rheumatol Int. 2023;43(8):1395–407. https://doi.org/10.1007/s00296-023-05306-5.

4. Anderson E, Furie R. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. Immunotherapy. 2020;12(5):275–86. https://doi.org/10.2217/imt-2020-0017.

5. Paley MA, Strand V, Kim AH. From mechanism to therapies in systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29(2):178–86. https://doi.org/10.1097/bor.0000000000000369.